Detection of Increased Choline Compounds with Proton Nuclear Magnetic Resonance Spectroscopy Subsequent to Malignant Transformation of Human Prostatic Epithelial Cells

Ellen Ackerstaff, Beth R. Pflug, Joel B. Nelson, and Zaver M. Bhujwalla

ABSTRACT

In this study, a panel of normal human prostate cells (HPCs) and tumor cells derived from metastases were studied by $^1$H NMR spectroscopy to determine whether the malignant transformation of HPCs results in the elevation of choline compounds. Although an elevated choline signal has been observed previously in clinical studies, the contribution of the different Cho compounds to this elevation, as well as their quantification, has not been established until now. Here we have shown that HPCs derived from metastases exhibit significantly higher phosphocholine as well as glycerophosphocholine levels compared with normal prostate epithelial and stromal cells. Thus the elevation of the choline peak observed clinically in prostate cancer is attributable to an alteration of phospholipid metabolism and not simply to increased cell density, doubling time, or other nonspecific effects. Androgen deprivation of the androgen receptor-positive cell lines resulted in a significant increase of choline compounds after chronic androgen deprivation of the LNCaP cell line and in a decrease of choline compounds after a more acute androgen deprivation of the LAPC-4 cell line. These data strongly support the use of proton magnetic resonance spectroscopic imaging to detect the presence of prostate cancer for diagnosis, to detect response subsequent to androgen ablation therapy, and to detect recurrence.

INTRODUCTION

Prostate cancer is the second leading cause of cancer related death among United States men (1). Early detection and diagnosis of prostate cancer are critically important factors in the prognosis of this disease. Currently, serum analysis of prostate-specific antigen levels, digital rectal examination, transrectal ultrasound, and biopsy are the standard methods for detecting and diagnosing prostate cancer (1). Several noninvasive imaging technologies are currently being evaluated with the purpose of obtaining a reliable in vivo marker to differentiate between benign and malignant tissue (2–4). These noninvasive techniques are also being explored for a “watchful waiting” approach to prostate cancer once diagnosed, to avoid unnecessarily aggressive treatments when not required. Of these technologies, localized $^1$H MRSI shows the most promise in detecting prostate cancer (2, 3). $^1$H NMR spectra localized in malignant prostatic tissue typically exhibit low levels of citrate and increased levels of tCho, which results in a high tCho to citrate ratio (2, 5, 6).

The tCho peak consists of PC, GPC, and free Cho, but the low resolution of in vivo spectroscopy does not allow identification of individual peaks from these compounds. To better understand the pathways underlying the changes in spectra observed in vivo, it is necessary to identify and quantify the changes in these Cho compounds after malignant transformation. We recently established, for a panel of human mammary epithelial cells, that both tCho and PC levels increased significantly with malignant progression (7). To establish further this pattern of Cho compounds after malignant transformation for other epithelial cells, in this study we determined the phospholipid profiles of normal HPCs and epithelial tumor cells. Primary human stromal cells originating in the prostate were also included in this panel to determine whether there were significant differences between the phospholipid profiles of stromal and epithelial prostatic cells.

Androgen ablation remains one of the standard therapies for metastatic prostate cancer, but these cancers can recur subsequent to anti-androgen therapy. Both AR-positive and -negative prostate tumor cells as well as androgen-deprived subclones of AR-positive cell lines were therefore included in the panel of HPCs studied. The ability to detect significant differences in phospholipids between androgen-dependent and androgen-independent cells would be useful not only for predicting which cancers would respond to androgen deprivation, but also in understanding the metabolic outcome of prostate cancer transition from androgen dependence to androgen independence.

MATERIALS AND METHODS

Cell Lines and Cell Culture. The phenotype and origin of the HPCs used in this study are described in Table 1. The PC-3, LNCaP, and DU-145 cells (purchased from American Type Culture Collection), TSU (8) and PPC-1 (9, 10) were grown in RPMI 1640 (Life Technologies, Inc.) containing 300 mg/liter $\gamma$-glutamine and 5.985 g/liter HEPES. Iscove’s modified Dulbecco’s medium (Life Technologies, Inc.) containing 292 mg/liter human epidermal growth factor (10) were grown in RPMI 1640 containing 300 mg/liter $\gamma$-glutamine and 5.985 g/liter HEPES. Iscove’s modified Dulbecco’s medium was supplemented with 10% FBS and penicillin (100 units/ml)/streptomycin (100 $\mu$g/ml). The LAPC-AD cell line was derived by growing LAPC-4 in Iscove’s modified Dulbecco’s medium without phenol red and supplemented with 10% charcoal-stripped FBS and penicillin (100 units/ml)/streptomycin (100 $\mu$g/ml). The primary epithelial cells PrEC and PrSC were purchased from Clonetics (Walkersville, MD). The PrEC cells were cultured in Opti Mem I (Life Technologies, Inc.) containing 292 mg/liter $\gamma$-glutamine and 2.4 mg/liter HEPES with penicillin (100 units/ml)/streptomycin (100 $\mu$g/ml) supplemented with the following reagents from BioWhittaker: (a) bovine pituitary extract (52 $\mu$g/ml); (b) human epidermal growth factor (10 ng/ml); (c) retinoic acid (0.1 $\mu$g/ml); (d) transferrin (50 $\mu$g/ml); (e) insulin (5 $\mu$g/ml); (f) hydrocortisone (1 $\mu$g/ml); (g) epinephrine (0.5 $\mu$g/ml); and (h) charcoal-stripped FBS (Hyclone). The year of initiating androgen deprivation was recorded.

Received 8/25/00; accepted 3/1/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by NIH Grant 1RO1 CA73850, CaP CURE CA74090-03, and the Mellam Family Foundation.

3 To whom requests for reprints should be addressed, at Magnetic Resonance Oncology Section, Division of Magnetic Resonance Research, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205. E-mail: [E.A, R.M.B] (Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224 [R.P.P., J.B.N.]; and Department of Urology, University of Pittsburgh, Shadyside Medical Center, Pittsburgh, Pennsylvania 15232 [R.P.P., J.B.N.].

3 Surveillance, Epidemiology, and End Results (SEER). Internet address: http://www.seer.cancer.gov.

2 The abbreviations used are: MRSI, magnetic resonance spectroscopic imaging; $^1$H, nuclear magnetic resonance; HPC, human prostate cell; AR, androgen receptor; FBS, fetal bovine serum; PCA, perchloric acid; Cho, choline; DT, doubling time; GPC, glycerophosphocholine; PC, phosphocholine; tCho, total choline; TSP, 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt; Vcm, cell volume.

3599
the internal standard TSP according to the equation:

where [metabolite] is the molar concentration of the metabolite, $A_{\text{TSP}}$ is the number of moles of TSP in the sample, $N_{\text{cell}}$ is the cell number, and $V_{\text{cell}}$ the cell volume calculated from the radius ($r$) of the cell (see Table 2) according to the equation, $V_{\text{cell}} = 4/3 \times \pi \times r^3$. Because the number of protons contributing to the signal of all of the Cho metabolites at 3.21–3.23 ppm and to the TSP peak at 0 ppm is the same, no correction for differences in the number of protons was required. For equation A to be valid, it is necessary that spectra are fully relaxed, as in this study, or to correct for saturation. The resulting metabolite concentrations were averaged for three separate cell culture experiments with separate batches of cells (five for TSU and four for LAPC-AD) for each cell line.

### Statistical Analysis

Statistical analyses were performed using Statview II version 1.04, 1991 (Abacus Concepts, Inc., Berkeley, CA). The differences in metabolite levels between cell lines were considered significant for $P \leq 0.05$, using the unpaired student t test (two-tailed).

### RESULTS

The AR status, the measured DT and $V_{\text{cell}}$ of the HPCs used in this study are presented in Table 2. The DT of the cells ranged from 15 to 30 h. From this table, it is apparent that the DT was not related to androgen dependence or independence or to the malignant status of the cells.

1H NMR spectra of the mortal prostate epithelial cells PrEC and the androgen independent PC-3 tumour cells presented in Fig. 1, revealed three water-soluble, Cho metabolites: free intracellular Cho at 3.207 ppm, PC at 3.224 ppm, and GPC at 3.233 ppm. The spectrum from PC-3 cells showed elevated PC and GPC signals compared with PrEC cells. The intracellular PC, GPC, and tCho concentrations for epithelial and stromal cells derived from healthy prostatic tissue compared with androgen-dependent and androgen-independent prostate cancer cell lines are summarized in Fig. 2. As evident in this figure, a significant ($P \leq 0.050$) elevation of PC, GPC, and tCho, compared with epithelial normal HPCs (PrEC), was observed for all of the tumour cell lines irrespective of their androgen status. Compared with stromal PrSC cells, all of the HPCs derived from metastases exhibited significantly higher PC levels, with the exception of LNCaP and DU-145, significantly higher GPC levels, with the exception of LNCaP, and significantly higher tCho levels, with the exception of LNCaP and DU-145.

The influence of androgen deprivation on PC, GPC, and tCho levels for the androgen-dependent tumour cell lines LNCaP and LAPC-4 is shown in Fig. 3. The response to androgen deprivation for LNCaP cells appears to be in marked contrast to that for LAPC-4 cells.
Long-term androgen deprivation (5–14 months) of the LNCaP cell line resulted in a significant increase in PC, GPC, and tCho concentrations in all subclones. Although the parent line, LNCaP did not exhibit significantly higher Cho metabolite levels compared with PrSC cells, and all of the androgen deprived subclones showed significantly increased Cho metabolites compared with PrSC cells. In contrast, androgen deprivation of 13 months in the LAPC-4 cell line, which exhibited much higher PC, GPC, and tCho levels to start with, produced a trend of decreased Cho compounds that were significant for GPC ($P < 0.05$) and tCho ($P < 0.07$), although all of the Cho metabolite levels were still significantly higher than in PrEC and PrSC cells.

**DISCUSSION**

The healthy adult prostate is enclosed in a capsule of fibrous connective tissue and smooth muscle fibers that extend into the gland and divide it into indistinct lobes. The stroma of the healthy prostate is comprised predominantly of smooth muscle corresponding with a high expression of smooth muscle $\alpha$-actin and low expression of vimentin (21). Because clinical MRSI may provide localized voxels with stromal as well as epithelial cell components, we included normal prostate stromal cells in our panel of HPCs. The concentrations of Cho-containing compounds were elevated in epithelial tumor cells compared with normal epithelial and stromal prostate cells. This elevation was independent of the androgen sensitivity of the tumor cells. These data are consistent with the elevation of the tCho peak, detected as an increase in Cho to citrate, in clinical $^1$H MRSI studies of prostate cancer (2), providing additional support for the use of the Cho signal as an in vivo marker of the presence of malignant prostate cells for diagnosis and treatment. Cho concentrations detected in the PCA extracts represent the water-soluble free Cho compounds. Studies have shown that the tCho peak detected in vivo is in excellent agreement with tCho measured in PCA extracts of the same tissue after excision (22, 23), and therefore the signal in vivo is also mainly from water-soluble free Cho compounds and not from membrane bound compounds. For purposes of in vivo detection, it is reasonable to assume that differences in tCho between normal and malignant prostate cells detected in PCA extracts will appear as differences in tCho in vivo with MRSI. Our observations are also consistent with recent PET studies that demonstrate increased uptake of $^{13}$C-Cho in prostate cancers and other malignancies (4, 24).

Our previous study on human mammary epithelial cells (7) dem-

![Fig. 2. PC (A), GPC (B), and tCho (C) concentrations (mean ± SE; three experiments) for a panel of HPCs comparing normal prostate cells of stromal and epithelial origin with androgen-dependent and -independent prostate tumor cells. Significant differences between tumor cell lines and the normal PrEC cells are marked by * ($P < 0.050$), and between tumor and PrSC cells are marked by † ($P < 0.050$).](#)

![Fig. 3. Effect of androgen deprivation on PC (A), GPC (B), and tCho (C) levels for the androgen-dependent cancer cell lines LNCaP and LAPC-4. Concentrations are in mM (mean ± SE) and averaged over three experiments (four experiments for LAPC-AD). Significant differences between HPCs derived from metastases and the PrEC cells are marked by * ($P < 0.050$) and between the PrSC cells are marked by † ($P < 0.050$).](#)
onstrated an increase of tCho with malignant transformation and the data on Cho obtained here for HPCs are similar to results obtained for mammary epithelial cells. However, prostate epithelial cells did not exhibit a switch from “high GPC and low PC” to “low GPC and high PC” after malignant transformation as observed for human mammary epithelial cells (7) and for immortalized, oncogene-transformed rat Schwann cells (25), suggesting that the pathways resulting in the alteration of the individual Cho compounds after malignant transformation may not be identical for mammary and prostatic epithelial cells.

Although the precise mechanisms underlying the alteration in phospholipid metabolism after malignant transformation are yet to be delineated, several possible explanations exist. At least two of these explanations may be ruled out from the cell culture conditions used in our study. For instance, it has been suggested that rapidly proliferating tissues such as tumors have increased membrane/fatty acid requirements, which may be responsible for the high Cho phospholipid metabolite levels in cancer versus healthy tissues (reviewed in Ref. 26). However, this explanation is the least plausible in our study. Because of the culture conditions, both normal prostate cell lines had DTs comparable with the HPC tumor cells. Alterations in concentrations of Cho compounds have also been observed as attributable to extra- and intracellular acidosis (27). Again this was largely ruled out in our study because of the frequent changing of culture medium that prevented any acidification of the medium.

The concentration of free Cho in the cell culture medium used was within a fairly narrow range (~20–30 μmol/liter) and high enough to avoid any effects attributable to Cho deprivation. The most plausible explanations for the alteration of Cho metabolites must therefore relate to pathways of Cho transport, incorporation and utilization. Of these, an increased Cho kinase activity and Cho transport (28–30) as well as increased phospholipase activity (31, 32) appear to be the most plausible. Although none of these mechanisms have been investigated in the HPCs studied here, there is some evidence for increased Cho transport and Cho kinase activity in breast cancer cells (28) and after oncogenic transformation (33–35). Similarly, Narayan et al. (36) have shown that, whereas phosphatidylcholine content in the membrane remained constant with malignant progression, the fatty acid composition of phosphatidylcholine and phosphatidylethanolamine was altered between benign prostatic hyperplasia and prostate cancer. The total content of palmitic acid was increased, whereas arachidonic acid was decreased in prostate cancer tissues compared with benign prostatic hyperplasia tissues. The decrease in arachidonic acid in the membrane phospholipids of prostate cancer was also confirmed in a study by Faas et al. (31), where a 2-fold increase in phospholipase A2 and a 4- to 12-fold higher fatty acyl-CoA lysophosphatidylcholine acyltransferase activity were observed in malignant versus benign human prostatic tissue.

Both androgen-dependent cell lines exhibited changes in Cho metabolites after androgen deprivation. Long-term androgen deprivation of the androgen-dependent LNCaP line (LN series) seemed to induce a more malignant phospholipid phenotype with higher levels of Cho compounds. The LN95, 96, 97, and 98 androgen-deprived cells also form xenograft tumors in nude mice more readily than the parental LNCaP cells, and can do so without Matrigel coincubated with the cells (37). The androgen-deprived LNCaP subclones also demonstrated increased colony formation in soft agar assays relative to the parental LNCaP cells. In contrast, androgen-deprivation of LAPC-4 cells over a shorter time period resulted in a decrease of GPC and tCho. Although the effects of chronic androgen deprivation are to be determined for LAPC-4 cells, these findings are consistent with results from Agues et al. (38) which indicate that androgen deprivation in prostate cancer produces cell cycle arrest rather than apoptosis, resulting in the emergence of androgen-independent sublines. These results also suggest that, although the initial Cho levels in prostate cancer cells seem to be high irrespective of androgen status, after androgen deprivation, the AR-positive lines showed a significant change in Cho metabolites. These data suggest that androgen deprivation therapy may be evaluated clinically by 1H MRSI. It is also possible that differences in the AR between the cell lines may contribute to the different response in phospholipid metabolism after androgen deprivation. Sequence analyses of the LNCaP cell AR revealed one point mutation in codon 868 (threonine—alanine substitution) in exon 8 located at the COOH-terminal end of the steroid-binding domain (39, 40). The mutant receptor displayed increased binding affinity for progesterone and estradiol. In addition, these ligands activate transcription at concentrations which would be inactive with the wild-type AR. In contrast, the AR of LAPC-4 contains wild-type sequences in the DNA and ligand-binding domain (11). In view of these differences in response to androgen deprivation, the impact of the point mutation of the AR in the LNCaP cell line on the phospholipid profile and prostate cancer progression deserves additional investigation.

ACKNOWLEDGMENTS

We acknowledge the expert technical assistance of Dr. V. P. Chacko in performing the NMR spectroscopy experiments.

REFERENCES

CHOLINE COMPOUNDS INCREASED IN MALIGNANT HPCS


Detection of Increased Choline Compounds with Proton Nuclear Magnetic Resonance Spectroscopy Subsequent to Malignant Transformation of Human Prostatic Epithelial Cells


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/61/9/3599

Cited articles  This article cites 39 articles, 8 of which you can access for free at: http://cancerres.aacrjournals.org/content/61/9/3599.full#ref-list-1

Citing articles  This article has been cited by 32 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/61/9/3599.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.